{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:32:11Z","timestamp":1790688731585,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000042","name":"amgen foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Peripheral neuropathy (PN) is a common consequence of multiple myeloma (MM) among those commonly treated with older-generation proteasome inhibitors (PIs). In this study, we evaluated the economic burden attributable to PN among MM patients in real-world practice settings in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Adults diagnosed with MM and first treated (index event) between 1 July 2006 and 28 February 2017 were identified from MarketScan\u00ae Commercial and Medicare claim databases. Continuous enrollment for at least 12 months without treatment and PN diagnoses were required pre-index. Patients were followed for at least 3\u2009months until inpatient death or end of data. The International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) and ICD-10-CM diagnosis codes were used to identify PN. Propensity-score matching was applied to match every patient with PN to two MM patients without a PN diagnosis (controls). Healthcare utilization and expenditures per patient per month (PPPM) in the postindex period were estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 11,851 patients meeting the study criteria, 15.5% had PN. After matching 1387 patients with PN and 2594 controls were identified. Baseline characteristics were well balanced between cohorts; mean follow up was 23\u201326\u2009months. PPPM total costs were significantly higher by $1509 for patients with PN than controls, driven by higher hospitalization (PN 77.4%, controls 67.2%; p &lt; 0.001) and emergency department rates (PN 67.8%, controls 58.4%; p &lt; 0.001) and more outpatient hospital-based visits PPPM (PN 13.5 \u00b1 14.7, controls 11.5 \u00b1 18.0; p &lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>PN is a prevalent MM treatment complication associated with a significant economic burden adding to the complexity and cost of MM treatment. Highly effective novel treatments such as carfilzomib may reduce the overall disease burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2040620719839025","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T06:37:29Z","timestamp":1554100649000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":35,"title":["Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7186-176X","authenticated-orcid":false,"given":"Xue","family":"Song","sequence":"first","affiliation":[{"name":"IBM Watson Health, 75 Binney Street, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Wilson","sequence":"additional","affiliation":[{"name":"IBM Watson Health, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Kagan","sequence":"additional","affiliation":[{"name":"IBM Watson Health, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"bibr1-2040620719839025","unstructured":"Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975\u20132011. Bethesda, MD: National Cancer Institute, 2014, http:\/\/seer.cancer.gov\/csr\/1975_2011\/ (accessed 14 March 2019)."},{"key":"bibr2-2040620719839025","unstructured":"American Cancer Society. What are the key statistics about multiple myeloma? http:\/\/www.cancer.org\/cancer\/multiplemyeloma\/detailedguide\/multiple-myeloma-key-statistics (2016, accessed 1 April 2018)."},{"key":"bibr3-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707596"},{"key":"bibr4-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"bibr5-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"bibr6-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"bibr7-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"bibr8-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"bibr9-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30147-8"},{"key":"bibr10-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.256"},{"key":"bibr11-2040620719839025","unstructured":"National Comprehensive Cancer Network. National comprehensive cancer network: multiple myeloma, http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf (2013, accessed 18 August 2018)."},{"key":"bibr12-2040620719839025","unstructured":"THALOMID\u00ae. Prescribing information: Thalomid (thalidomide). Summit, NJ: Celgene Corporation, https:\/\/media.celgene.com\/content\/uploads\/thalomid-pi.pdf (2017, accessed 14 March 2019)."},{"key":"bibr13-2040620719839025","unstructured":"VELCADE\u00ae. Prescribing information: Velcade (bortizumib). Cambridge, MA: Millennium Pharmaceuticals, Inc. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021602s042lbl.pdf (2015, accessed 5 October 2018)."},{"key":"bibr14-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.11.003"},{"key":"bibr15-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70068-1"},{"key":"bibr16-2040620719839025","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012674"},{"key":"bibr17-2040620719839025","unstructured":"American Cancer Society. Peripheral neuropathy caused by chemotherapy, https:\/\/www.cancer.org\/treatment\/treatments-and-side-effects\/physical-side-effects\/peripheral-neuropathy.html (2015, accessed 1 April 2018)."},{"key":"bibr18-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos203"},{"key":"bibr19-2040620719839025","first-page":"4","volume":"11","author":"Trivedi MS","year":"2015","journal-title":"Am J Hematol Oncol"},{"key":"bibr20-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds329"},{"key":"bibr21-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1105202"},{"key":"bibr22-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"bibr23-2040620719839025","unstructured":"United States Bureau of Labor Statistics. Consumer price index, http:\/\/www.bls.gov\/cpi\/ (2018, accessed 1 June 2018)."},{"key":"bibr24-2040620719839025","first-page":"913848","volume":"2012","author":"Pike CT","year":"2012","journal-title":"Chemother Res Pract"},{"key":"bibr25-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-5-441"},{"key":"bibr26-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"bibr27-2040620719839025","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"bibr28-2040620719839025","volume":"122","author":"Martin III TG","year":"2013","journal-title":"Blood"},{"key":"bibr29-2040620719839025","unstructured":"POMALYST\u00ae. Prescribing information: Pomalyst (pomalidomide). Summit, NJ: Celgene Corporation, http:\/\/www.celgene.com\/content\/uploads\/pomalyst-pi.pdf (2018, accessed 18 April 2018)."},{"key":"bibr30-2040620719839025","unstructured":"KYPROLIS\u00ae. Prescribing information: Kyprolis (carfilzomib). Thousand Oaks, CA: Amgen Inc. http:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/kyprolis\/kyprolis_pi.ashx (2018, accessed 18 April 2018)."},{"key":"bibr31-2040620719839025","unstructured":"DARZALEX\u00ae. Prescribing information: Darzalex (daratumumab), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761036s004lbl.pdf (2016, accessed 18 April 2018)."},{"key":"bibr32-2040620719839025","unstructured":"EMPLICITI\u00ae. Prescribing information: Empliciti (elotuzumab). Princeton, NJ: Bristol-Myers Squibb Company, http:\/\/packageinserts.bms.com\/pi\/pi_empliciti.pdf?&utm_source=bing&utm_medium=cpc&utm_campaign=managementbnd&utm_term=prescribinginformation&utm_content=managementbnd_sitelink_pi_empliciti.pdf_text (2017, accessed 18 April 2018)."}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620719839025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2040620719839025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620719839025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:14:24Z","timestamp":1777590864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2040620719839025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":32,"alternative-id":["10.1177\/2040620719839025"],"URL":"https:\/\/doi.org\/10.1177\/2040620719839025","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"2040620719839025"}}